A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to further advancements in biospecimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine, for lung cancer management and lung cancer screening (synergy with imaging). A co-clinical trial approach, with integrative analyses leveraging data from the treatment of genetic mouse models of lung cancer along with clinical samples and data from lung cancer patients, will be used to elucidate genomic background metrics, identify cell free DNA mutations, and further refine the liquid biopsy approach. Blood and urine samples will be analyzed for different genetic components. The tissue biopsy will be implanted into a mouse and after the cancer grows in the mouse the cancer DNA from the mouse will be compared with the human blood.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

NCT05384769

Lung Carcinoma

RECRUITING NA

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

NCT01414595

Lung Cancer

COMPLETED

Cell Free DNA for the Diagnosis and Treatment in Early NSCLC

NCT03791034

Non-small Cell Lung Cancer

RECRUITING

Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

NCT03492801

Stage III Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Non-Small Cell Lung Cancer AJCC v7 +1 more

TERMINATED

Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer

NCT01517971

Lung Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a feasibility study to collect tumor and peripheral blood and urine of patients with lung cancer, or head and neck cancer, or other solid tumor who receive treatment. Blood and urine will also be collected from subjects without cancer to assess non cancer profiles. To conduct this study, a total of 30 study-eligible subjects of all races and ethnicities, aged 18 years or older with a diagnosis of cancer of the lung or head and neck cancer or other solid tumor malignancy (Cohort A), will be enrolled and have their tumor collected once for molecular profiling and xenograft development and blood collected at prespecified time intervals until completion of treatment for liquid biopsy analysis (targeted sequencing, whole exome sequencing, whole genome sequencing). A total of 140 study-eligible subjects of all races and ethnicities ages 18 years or older will be enrolled in the non-lung cancer control subgroups for chronic inflammatory disorder (Cohort B), people at risk to develop lung cancer (Cohort C) and healthy people who complete vigorous exercise (Cohort D). A total of 180 subjects will be enrolled into the resection and radiation therapy cancer cohorts (Cohorts E and F).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fresh tissue biopsy

Fresh tissue biopsy will be collected.

Intervention Type OTHER

Blood/Urine Sample Collection

A one time blood sample will be collected.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Unresectable metastatic lung cancer or head and neck cancer or other solid tumor malignancy
2. Current or Former Smokers with greater than or equal to 10 pack year smoking history
3. Candidates for standard or experimental treatment as determined by their treating physician
4. Age 18 years and older
5. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)

1. Chronic inflammatory disease including but not limited to:

* Systematic Lupus Erythematosus
* Rheumatoid arthritis
* Hepatitis C
* Ankylosing Sponsylitis
* Scleroderma
2. No history of smoking or quit smoking within the last six months
3. Age 18 years and older
4. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)

1. Age 45-74 years
2. Former or current smokers with a 30 or more pack-years of cigarette smoking history
3. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)

1. Age 18 years and older
2. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
3. Must complete and self-report vigorous exercise for 30 minutes

1. Age 18 years and older
2. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
3. Lung cancer with planned resection.

1. Age 18 years and older
2. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
3. Any solid tumor cancer and will receive radiation therapy.

Exclusion Criteria

1. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen
2. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.
3. Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol
4. Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol
5. Other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen

1\. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen. 2. Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol.

3\. Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol.

4\. Other current malignancy(s). Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration. Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration.

5\. No current steroid treatment or treatment within the last 3 months.

1. Other current malignancy(s). Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration. Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration.
2. History of lung cancer
3. History of removal of any portion of the lung, excluding needle biopsy
4. Unexplained weight loss of more than 15 pounds in the 12 months prior to eligibility assessment
5. Recent hemoptysis
6. Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks prior to eligibility assessment.
7. History of abnormal chest CT examination suspicious for cancer in the 18 months prior to eligibility assessment.

9\. Chronic inflammatory disease including but not limited to:

* Systematic Lupus Erythematosus
* Rheumatoid arthritis
* Hepatitis C
* Ankylosing Sponsylitis
* Scleroderma

1\. People will be excluded if they have self reported any of the following conditions: diabetes, heart disease, autoimmune disorders or hepatitis.

1. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the protocol
2. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.

1\. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the protocol 3. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes